Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Thromboembolic events more likely among CIDP patients with CVAD

Key clinical point: Patients with chronic inflammatory demyelinating polyneuropathy (CIDP) receiving intravenous immunoglobulin (IVIg) may have increased risk of thrombosis with CVAD.

Major finding: Among patients with CIDP receiving IVIg, 25% with CVADs and 11.2% without CVADs had a thromboembolic event (P less than .0001).

Study details: The findings are based on an retrospective U.S. claims data cohort study of 7,447 people with CIDP who received IVIg between 2006 and 2018.

Disclosures: The research was funded by CSL Behring. Dr. Patel and two of the other five authors are employees of CSL Behring.


Patel A et al. AANEM 2019, Abstract 94.